Standout Papers

Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised,... 2019 2026 2021 2023 387
  1. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial (2019)
    Richard E. Pratley, Aslam Amod et al. The Lancet

Immediate Impact

1 from Science/Nature 60 standout
Sub-graph 1 of 23

Citing Papers

Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
2025 Standout
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
2025 Standout
3 intermediate papers

Works of Trine Saugstrup being referenced

Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial
2019 Standout
Incorporating and interpreting regulatory guidance on estimands in diabetes clinical trials: The PIONEER 1 randomized clinical trial as an example
2019

Author Peers

Author Last Decade Papers Cites
Trine Saugstrup 125 94 272 383 8 584
Irina Kline 113 175 230 339 12 520
Jeanne Hejna 42 206 89 483 11 563
Daishiro Yamada 32 67 209 235 17 531
Kristin Ohneberg 35 285 210 515 10 661
Yayoi Hosoki 128 63 251 121 13 676
Elsa Pennese 48 85 92 127 9 720
Nelun Wijayasinghe 14 225 310 493 12 710
R A Castro 15 168 337 218 11 717
Junna Yamaguchi 37 92 211 134 16 607
Sakurako Nakamura 34 69 128 132 15 668

All Works

Loading papers...

Rankless by CCL
2026